193 related articles for article (PubMed ID: 28471446)
1. Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.
Huo Q; Ge C; Tian H; Sun J; Cui M; Li H; Zhao F; Chen T; Xie H; Cui Y; Yao M; Li J
Cell Death Dis; 2017 May; 8(5):e2766. PubMed ID: 28471446
[TBL] [Abstract][Full Text] [Related]
2. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
3. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
[TBL] [Abstract][Full Text] [Related]
4. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
6. Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT.
Zhou HH; Chen L; Liang HF; Li GZ; Zhang BX; Chen XP
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110775
[TBL] [Abstract][Full Text] [Related]
7. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
Xia P; Zhang H; Xu K; Jiang X; Gao M; Wang G; Liu Y; Yao Y; Chen X; Ma W; Zhang Z; Yuan Y
Cell Death Dis; 2021 Jul; 12(7):691. PubMed ID: 34244479
[TBL] [Abstract][Full Text] [Related]
8. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
Giovannini C; Baglioni M; Baron Toaldo M; Ventrucci C; D'Adamo S; Cipone M; Chieco P; Gramantieri L; Bolondi L
Oncotarget; 2013 Oct; 4(10):1618-31. PubMed ID: 24113128
[TBL] [Abstract][Full Text] [Related]
9. ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma.
Zhang L; Huo Q; Ge C; Zhao F; Zhou Q; Chen X; Tian H; Chen T; Xie H; Cui Y; Yao M; Li H; Li J
Cancer Res; 2020 Jun; 80(12):2599-2611. PubMed ID: 32312832
[TBL] [Abstract][Full Text] [Related]
10. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
12. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Yan Y; Wang L; He J; Liu P; Lv X; Zhang Y; Xu X; Zhang L; Zhang Y
Biomed Pharmacother; 2017 Apr; 88():395-402. PubMed ID: 28122304
[TBL] [Abstract][Full Text] [Related]
13. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
14. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
15. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
17. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
18. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
19. 1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1).
Huang J; Yang G; Huang Y; Kong W; Zhang S
Mol Med Rep; 2016 Feb; 13(2):1373-80. PubMed ID: 26676829
[TBL] [Abstract][Full Text] [Related]
20. Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf/Cip1) stabilization by activating the ERK1/2-MAPK pathway.
Zhang Y; Liu Y; Duan J; Yan H; Zhang J; Zhang H; Fan Q; Luo F; Yan G; Qiao K; Liu J
Hepatology; 2016 Mar; 63(3):880-97. PubMed ID: 26659654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
